CBD Oil in Mechanical Back Pain
Unknown statusNCT04726579
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
This study is a 12-week open-label, prospective, observational study to assess how subjects with chronic mechanical back pain respond to cannabidiol (CBD)
Study details
- Official title
- An Open-Label, Prospective, Observational Study to Assess the Response to Cannabidiol (CBD) Oil in Subjects With Chronic Mechanical Back Pain (MBP)
- Conditions
- Sponsor
- perceiveMD
- Start date
- 2021-03-01
- Primary completion
- 2021-12-31
- Sex
- All
- Age range
- from 21 Years
- Results posted
- No results posted in this snapshot
- Total sites listed
- 0
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1\) Must be able to communicate well with the Investigator(s), understand and comply with the requirements of the study, and provide written consent 2\. Age ≥21 years 3\. Diagnosed with MBP with symptom onset \>3 months prior to screening visit 4\. Must have pain severity ≥4/10 on VAS for at least 3 months as reported by the patient 5\. Decided to take CBD oil for the treatment of MBP 6\. Must have access to a computer or laptop and be able to operate the required video conference platform Exclusion Criteria: * 1\. Cause of pain due to malignancy, infection, fracture, or spondylarthritis 2\. Recent (within the last 3 months) spinal trauma 3\. Leg dominant/radicular pain 4\. Current active fibromyalgia 5\. Female who is pregnant, nursing, or plan to become pregnant during the study 6\. Allergies to CBD or any components of the CBD oil to be used in the study 7\. Active significant medical and/or psychological illness which, in the opinion of the Investigator, is not suitable to participate in the study (e.g. malignancy, hepatic disease, CAD, COPD, schizophrenia, etc.) 8\. Changes in doses of baseline analgesics such as acetaminophen, pregabalin, gabapentin, opioids, or glucocorticoids within 1 month prior to the study
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT04726579